REACT study– PEER-REVIEWED publications 2020-2024
2020
1. Flower B, Brown JC, Simmons B, Moshe M, Frise R, Penn R, Kugathasan R, Petersen C, Daunt A, Ashby D, Riley S, Atchison CJ, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Khan M, Fernandez N, Sureda-Vives M, Cheeseman HM, O'Hara J, Fontana G, Pallett SJC, Rayment M, Jones R, Moore LSP, McClure MO, Cherepanov P, Tedder R, Ashrafian H, Shattock R, Ward H, Darzi A, Elliott P, Barclay WS, Cooke GS. (2020). Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. THORAX. 1 Dec 2020. 75(12), 1082-1088. 2 Aug 2020. doi:10.1136/thoraxjnl-2020-215732
2. Atchison C, Pristerà P, Cooper E, Papageorgiou V, Redd R, Piggin M, Flower B, Fontana G, Satkunarajah S, Ashrafian H, Lawrence-Jones A, Naar L, Chigwende J, Gibbard S, Riley S, Darzi A, Elliott P, Ashby D, Barclay W, Cooke GS, Ward H. Usability and acceptability of home-based self-testing for SARS-CoV-2 antibodies for population surveillance. CLIN INFECT DIS. 2020 Aug 12:ciaa1178. doi: 10.1093/cid/ciaa1178
3. Riley, S., Atchison, C., Ashby, D., Donnelly, C. A., Barclay, W., Cooke, G., Ward H, Darzi., Elliott, P; REACT Study Group. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. WELLCOME OPEN RESEARCH, 5, 200. 25 Aug 2020. https://doi.org/10.12688/wellcomeopenres.16228.2 vs.2, April 21, 2021.
2021
4. Moshe M, Daunt A, Flower B, Simmons B, Brown JC, Frise R, Penn R, Kugathasan R, Petersen C, Stockmann H, Ashby D, Riley S, Atchison C, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Marchesin F, Fernandez N, Sureda-Vives M, Cheeseman H, O’Hara J, Shattock R,Fontana G, Pallett SJC, Rayment M, Jones R, Moore LSP, Ashrafian H, Cherapanov P, Tedder R, McClure M, Ward H, Darzi A, Elliott P, Cooke GS, Barclay WS. SARS- CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BR MED J. 2021; 372:, doi:10.1136/bmj.n423
5. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, Redd R, Ashby D, Donnelly C, Barclay Darzi, Cooke, Riley S, Elliott P. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. NAT COMMUN, 2021; 2(1), 905.
https://www.nature.com/articles/s41467-021-21237-w
6. Ward, H., Cooke, G. S., Atchison, C., Whitaker, M., Elliott, J., Moshe, M., Brown JC, Flower B, Daunt A, Ainslie K, Ashby D, Donnelly CA, Riley S, Darzi A, Barclay W, Elliott P. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. LANCET REGIONAL HEALTH-EUROPE 2021; 4, 100098. doi:10.1016/j.lanepe.2021.100098
7. Davies, B., Parkes, B.L., Bennett, J. Fecht, D., Blangiardo, M., Ezzati, Elliott, P. Community factors and excess mortality in first wave of the COVID-19 pandemic in England. NAT COMMUN 2021; 12, 3755. https://doi.org/10.1038/s41467-021-23935-x. June 18, 2021.
8. Riley S, Ainslie KEC, Eales O, Walters, CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi A, Elliott P. Resurgence of SARS-CoV-2: detection by community viral surveillance. SCIENCE 2021; 372(6545): 990-995. doi: 10.1126/science.abf0874. April 23, 2021.
9. Redd R, Cooper E, Atchison C, Pereira I, Hollings P, Cooper T, Millar C, Ashby D, Riley S, Darzi A, Barclay W, Cooke GS, Elliott P, Donnelly CA, Ward H Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. WELLCOME OPEN RESEARCH, 6, 203. doi:10.12688/wellcomeopenres.16662.1
10. Elliott, J., Whitaker, M., Bodinier, B., Eales, O., Riley, S., Ward, H, Cooke G, Darzi A, Chadeau-Hyam M, Elliott, P. Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLOS MED, 2021; 18(9), e1003777. doi:10.1371/journal.pmed.1003777
11. Davies, B., Araghi, M., Moshe, M., Gao, H., Bennet, K., Jenkins, J., Atchison, G, Darzi A, Ashby D, Riley S, Barclay W, Elliott P, Ward H, Cooke, G. Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. OPEN FORUM INFECT DIS, 2021; 8(11), ofab496. doi:10.1093/ofid/ofab496
12. Redd, R., Cooper, E., Atchison, C., Pereira, I., Hollings, P., Cooper, T., Millar C, Ashby D, Riley S, Darzi A, Barclay WS, Cooke GS, Elliott P, Donnelly CA, Ward, H. Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. WELLCOME OPEN RESEARCH, 6, 203. doi:10.12688/wellcomeopenres.16662.2
13. Elliott, P., Haw, D., Wang, H., Eales, O., Walters, C. E., Ainslie, K. E. C., Atchison C, Fronterre C, Diggle PJ, Page AJ, Trotter AJ, Prosolek SJ, Ashby D, Donnelly CA, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley, S. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. SCIENCE, 2021; 374(6574), 1463-73. eabl9551. doi:10.1126/science.abl9551
14. Cann, A., Clarke, C., Brown, J., Thomson, T., Prendecki, M., Moshe, M., Badhan A, Simons B, Klaber B, Elliott P, Darzi A, Riley S, Ashby D, Martin P, Gleeson S, Willicombe M, Kelleher P, Ward H, Barclay W, Cooke, G. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. WELLCOME OPEN RESEARCH 2021; 6: 358. doi:10.12688/wellcomeopenres.17231.1
15. Elliott, P., Bodinier, B., Eales, O., Wang, H., Haw, D., Elliott, J., Whitaker M, Jonnerby J, Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly, C. A. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. SCIENCE, 2022. eabn8347. doi: 10.1126/science.abn8347
2022
16. Khan, M., Rosadas, C., Katsanovskaja, K., Weber, I. D., Shute, J., Ijaz, S., Marchesin F, McClure E, Elias S, Flower B, Gao H, Quinlan R, Short C, Rosa A, Roustan C, Moshe M, Taylor GP, Elliott P, Cooke GS, Cherepanov P, Parker E, McClure MO, Tedder, R. S. (2022). Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies. SCIENTIFIC REPORTS, 2022; 12(1). doi:10.1038/s41598-022-05640-x. https://www.nature.com/articles/s41598-022-05640-x
17. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Donnelly CA, Elliott P, COVID-19 Genomics UK consortium. SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. LANCET RESPIR MED. 2022. doi:10.1016/S2213-2600(21)00542-7. https://doi.org/10.1016/S2213-2600(21)00542-7
18. Ward, H., Whitaker, M., Flower, B., Tang, S. N., Atchison, C., Darzi, A., Donnelly CA, Cann A, Diggle PJ, Ashby D, Riley S, Barclay WS, Elliott P, Cooke, G. S. Population antibody responses following COVID-19 vaccination in 212,102 individuals. NAT COMMUN, 2022; 13(1): 907. doi: 10.1038/s41467-022-28527-x
19. Eales, O., Walters, C. E., Wang, H., Haw, D., Ainslie, K. E. C., Atchison, C. J., Page AJ, Prosolek S, Trotter AJ, Le Viet T, Alikhan N-F, Jackson LM, Ludden C, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi A, Elliott P, Riley, S. (n.d.). Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. WELLCOME OPEN RESEARCH, 2022; 7, 102. doi:10.12688/wellcomeopenres.17723.1
20. Elliott, P., Bodinier, B., Eales, O., Wang, H., Haw, D., Elliott, J , Whitaker M, Jonnerby J, Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly, C. A. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. SCIENCE, 2022; 375(6587), 1406-+. doi:10.1126/science.abn8347
21. Rosadas, C., Khan, M., Parker, E., Marchesin, F., Katsanovskaja, K., Sureda-Vives, M. Fernandez N, Randell P, Harvey R, Lilley A, Harris BHL, Zuhair M, Fertleman M, Ijaz S, Dicks S, Short C-E, Quinlan R, Taylor GP, Hu K, McKay P, Rose A, Roustan C, Zuckerman M, El Bouzidi K, Cooke G, Flower B, Moshe M, Elliott P, Spencer AJ, Lambe T, Giklbvert SC, Kingston H, Baillie JK, Openshaw PJM, Semple MG, Cherepanov P, McClure MO, Tedder, R. S. (2022). Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. J VIROL METHODS. 2022; 302. doi:10.1016/j.jviromet.2022.114475
22. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Donnelly CA, Elliott P. COVID-19 Genomics UK consortium. SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. LANCET RESPIR MED, 2022; 10(4): 355-366. doi:10.1016/S2213-2600(21)00542-7
23. Whitaker, M., Elliott, J., Chadeau-Hyam, M., Riley, S., Darzi, A., Cooke, G.,Ward, H, Elliott, P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. NATURE COMMS. 2022; 13(1). doi:10.1038/s41467-022-29521-z
24. Elliott, P., Eales, O., Steyn, N., Tang, D., Bodinier, B., Wang, H., Elliott J, Whitaker M, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Donnelly CA, Chadeau-Hyam, M. (2022). Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. SCIENCE, eabq4411. doi:10.1126/science.abq4411
25. Cann, A., Clarke, C., Brown, J., Thomson, T., Prendecki, M., Moshe, M., Badhan A, Simmons B, Klaber B, Elliott P, Darzi A, Riley S, Ashby D, Martin P, Gleeson S, Willicombe M, Kelleher P, Ward H, Barclay WS, Cooke, G. S. (2021). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. WELLCOME OPEN RES, 6, 358. doi:10.12688/wellcomeopenres.17231.2
26. Chadeau-Hyam, M., Eales, O., Bodinier, B., Wang, H., Haw, D., Whitaker, M., Elliott J, Walters CE, Jonnerby J, Atchison C, Diggle PJ, Page AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Donnelly CA, Elliott, P. (2022). Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. ECLINICALMEDICINE, 48, 101419. doi:10.1016/j.eclinm.2022.101419
27. Wong, N. C. K., Meshkinfamfard, S., Turbé, V., Whitaker, M., Moshe, M., Bardanzellu, A., Dai T, Pignatelli E, Barclay W, Darzi A, Elliott P, Ward H, Tanaka RJ, Cooke GS, McKendry RA, Atchison CJ, Bharath, A. A. (2022). Machine learning to support visual auditing of home-based lateral flow immunoassay self-test results for SARS-CoV-2 antibodies. COMMUN MED (LOND), 2, 78. doi:10.1038/s43856-022-00146-z
28. Eales, O., Page, A. J., Martins, L. D. O., Wang, H., Bodinier, B., Haw, D., Jonnerby J, Atchison C, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi , Riley S, Chadeau-Hyam M, Donnelly CA, Elliott, P. (2022). SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. BMC INFECTIOUS DISEASES, 22(1), 17 pages. doi:10.1186/s12879-022-07628-4
29. Eales, O., Martins, L. D. O., Page, A. J., Wang, H., Bodinier, B., Tang, D., Haw D, Jonnerby J, Atchison C, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Elliott P, Donnelly CA, Chadeau-Hyam, M. (2022). Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. NATURE COMMUNICATIONS, 13(1), 11 pages. doi:10.1038/s41467-022-32096-4
30. Atchison, C. J., Moshe, M., Brown, J. C., Whitaker, M., Wong, N. C. K., Bharath, A. A., McKendry RA, Darzi A, Ashby D, Donnelly CA, Riley S, Elliott P, Barclay WS, Cooke S, Ward, H. (2022). Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Detection by Lateral Flow Immunoassay. CLINICAL INFECTIOUS DISEASES, 9 pages. doi:10.1093/cid/ciac629
31. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw D, Elliott J, Whitaker M, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M . . . Donnelly, C. A. (2022). Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England. NATURE COMMUNICATIONS, 13(1), 10 pages. doi:10.1038/s41467-022-32121-6
32. Eales, O., Ainslie, K. E. C., Walters, C. E., Wang, H., Atchison, C., Ashby, D., Donnelly CA, Cooke G, Barclay W, Ward H, Darzi A, Elliott P, Riley, S. (2022). Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. EPIDEMICS, 40, 13 pages. doi:10.1016/j.epidem.2022.100604
33. Chadeau-Hyam, M., Tang, D., Eales, O., Bodinier, B., Wang, H., Jonnerby, J., Whitaker M, Elliott J, Haw D, Walters CE, Atchison C, Diggle PJ, Page AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Donnelly CA , Elliott, P. (2022). Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys. LANCET REG HEALTH EUR, 21, 100462. doi:10.1016/j.lanepe.2022.100462
34. Mosscrop, L., Watber, P., Elliott, P., Cooke, G., Barclay, W., Freemont, P. S., Rosadas, C., Taylor, G. P. (2022). Evaluation of the impact of pre-analytical conditions on sample stability for the detection of SARS-CoV-2 RNA. J Virol Methods, 309, doi:10.1016/j.jviromet.2022.114607
35. Whitaker, M., Elliott, J., Bodinier, B., Barclay, W., Ward, H., Cooke, G., Donnelly CA, Chadeau-Hyam M, Elliott, P. (2022). Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun, 13(1), 6856. doi:10.1038/s41467-022-34244-2
36. Eales, O., Wang, H., Haw, D., Ainslie, K. E. C., Walters, C. E., Atchison, C., Cooke G, Barclay W, Ward H, Darzi A, Ashby D, Donnelly CA, Elliott P, Riley, S. (2022). Trends in SARS-CoV-2 infection prevalence during England's roadmap out of lockdown, January to July 2021.. PLoS Comput Biol, 18(11), e1010724. doi:10.1371/journal.pcbi.1010724
2023
37. Cooper, E., Lound, A., Atchison, C. J., Whitaker, M., Eccles, C., Cooke, G. S., Elliott P, Ward, H. (2023). Awareness and perceptions of Long COVID among people in the REACT programme: Early insights from a pilot interview study. PLoS One, 18(1), e0280943. doi:10.1371/journal.pone.0280943
38. Eales, O., Page, A. J., Tang, S. N., Walters, C. E., Wang, H., Haw, D.,, Trotter, A., Le Viet, L, Foster-Nyarko, E., Prosolek, S., Atchison, C., Ashby, D., Cooke, G., Barclay, W., Donnelly, C., O’Grady, J., Volz, E., Darzi, A., Ward, H., Elliott, P., Riley, S. The use of representative community samples to assess SARS-CoV-2 lineage competition: Alpha outcompetes Beta and wild-type in England from January to March 2021. Microbial Genomics. 2023, February, 9(2). doi:10.1099/mgen.0.000887
39. Atchison, C. J., Whitaker, M., Donnelly, C. A., Chadeau-Hyam, M., Riley, S., Darzi, A., Ashby, D., Barclay, W., Cooke, G.S., Elliott, P., Ward, H. Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England. Archives Dis Child, March 2023. doi:10.1136/archdischild-2022-325152
40. Elliott, P., Ward, H., Riley, S. Population Monitoring of SARS-CoV-2 Infections via Random Sampling During the COVID-19 Pandemic. Am J Public Health, 2023; 113(5), 514-516. doi:10.2105/AJPH.2023.307231
41. Routen, A., O'Mahoney, L., Aiyegbusi, O. L., Alder, Y., Banerjee, A., Buckland, L., Brightling, C., Calvert, M., Camaradou, J., Chaturvedi, N., Chong, A., Dalrymple, E., Eggo, R.M., Elliott, P., Evans, R.A., Gibson, A., Harons, S., Herrett, E., Houchen-Wolloff, L., Hughes, S.E., Jeyes, F., Matthews, K., McMullan, C., Morley, J., Shafran, R., Smith, N., Stanton, D., Stephenson, T., Sterne, J., Turner, G.M., Ward, H., Khunti, K. (2023). Patient and public involvement within epidemiological studies of long COVID in the UK. Nat Med, 29(4), 771-773. doi:10.1038/s41591-023-02251-5
42. Elliott, P., Whitaker, M., Tang, D., Eales, O., Steyn, N., Bodinier, B., Wang, H., Elliott, J., Atchison, C., Ashby, D., Barclay, W., Taylor, G., Darzi, A., Cooke, G., Darzi, A., Cooke, G.S., Ward, H., Donnelly, C.A., Riley, S., Chadeau-Hyam, M. (2023). Design and Implementation of a National SARS-CoV-2 Monitoring Program in England: REACT-1 Study. Am J Public Health, 113(5), 545-554. doi:10.2105/AJPH.2023.307230
43. Eales, O., Haw, D., Wang, H., Atchison, C., Ashby, D., Cooke, G. S., Barclay, W., Ward, H., Darzi, A., Donnelly, C.A., Chadeau-Hyam, M., Elliott, P., Riley, S. (2023). Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England. PLoS Biol, 21(5), e3002118. doi:10.1371/journal.pbio.3002118
44. Atchison CJ, Whitaker M, Donnelly CA, Chadeau-Hyam M, Riley S, Darzi A, Ashby D, Barclay W, Cooke GS, Elliott P, Ward H. Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England. Arch Dis Child. 2023 l;108(7):e12. doi: 10.1136/archdischild-2022-325152.
45. Whitaker, M, Davies B, Atchison C, Barclay W, Ashby D, Darzi A, Riley S, Cooke G, Donnelly CA, Chadeau-Hyam M, Elliott P, Ward H. SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people. Nat Commun 14, 4957 (2023). https://doi.org/10.1038/s41467-023-40643-w.
46. Eales, I., de Oliveira, Martins, L., Page, A., Wang, H., Bodinier, B., Tang, D., Haw, D., Jonnerby, L.J.A., Atchison, C., Ashby, D., Barclay, W., Taylor, G., Coke, G., Ward, H., Darzi, A., Riley, S., Elliott, P., Donnelly, C., Chadeau, M. (2023). Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England. Nature Comm, 13. doi: 10.1038/s41467-022-32096-4
47. Ward, H., Atchison, C., Whitaker, M., Davies, B., Ashby, D., Darzi, A., Chadeau-Hyam, M, Riley, S, Donnelly, CA, Barclay W, Cooke, G, Elliott, P. (2023). Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study.. Am J Public Health, 113(11), 1201-1209. doi:10.2105/AJPH.2023.307381
48. Atchison, C. J., Davies, B., Cooper, E., Lound, A., Whitaker, M., Hampshire, A., Azor A, Donnelly, CA, Chadeau-Hyam, M, Cooke, G, Elliott, P. (2023). Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun, 14(1), 6588. doi:10.1038/s41467-023-41879-2
2024
49. Hampshire, A., Azor, A., Atchison, C., Trender, W., Hellyer, P. J., Giunchiglia, V., Husain, M., Cooke, G., Cooper, E., Lound, A., Donnelly, CA., Chadeau-Hyam, M., Ward, H., Elliott, P. (2024). Cognition and Memory after Covid-19 in a Large Community Sample.. N Engl J Med, 390(9), 806-818. doi:10.1056/NEJMoa2311330
REACT study scientific reports – non-PEER-REVIEWED 2020-2022
1. REACT Study Investigators, Riley S, Ainslie KEC, Eales O, Jeffrey B, Walters CE, Wang H, Atchison C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT Study. MedRxiv July 11, 2020. https://doi.org/10.1101/2020.07.10.20150524
2. React Study Investigators, Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. Transient dynamics of SARS-CoV-2 as England existed national lockdown. MedRxiv August 6, 2020. https://doi.org/10.1101/2020.08.05.20169078
3. React Study Investigators, Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. Resurgence of SARS-CoV-2 as England: Detection by community antigen surveillance. MedRxiv September 13, 2020. doi: https://doi.org/10.1101/2020.09.11.20192492v2
4. React Study Investigators, Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. High prevalence of SARS-CoV-2 swab positivity in England during September 2020: Interim report of Round 5 of REACT-1 Study. MedRxiv October 2, 2020. doi: https://doi.org/10.1101/2020.09.30.20204727
5. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. High and increasing prevalence of SARS-CoV-2 swab positivity in England: REACT-1 Round 5 Updated Report. MedRxiv October 14, 2020. doi: https://doi.org/10.1101/2020.10.12.20211227v1
6. Ward, H., Cooke, G., Atchison, C., Whitaker, M., Elliott, J., Moshe, M., Flower B, Daunt A, Ainslie K, Ashby D, Donnelly C, Riley S, Darzi A, Barclay W, Elliott P; for the REACT study team. (2020). Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. MedRxiv October 27, 2020. doi: https://doi.org/10.1101/2020.10.26.20219725
7. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 Round 6 Interim Report. MedRxiv 3 November 2020. doi: https://doi.org/10.1101/2020.10.30.20223123
8. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. REACT-1 Round 6 Updated Report. High prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020: MedRxiv November 20, 2020. doi: https://doi.org/10.1101/2020.11.18.20233932v1
9. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. REACT Round 7 Interim Report: Fall in prevalence of SARS-CoV-2 swab positivity in England During National Lockdown. MedRxiv December 2, 2020. doi: https://doi.org/10.1101/2020.11.30.20239806
10. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. REACT Round 7 Updated Report: Regional heterogeneity in changes in prevalence of SARS-CoV-2 infections during the second National COVID-19 Lockdown in England. MedRxiv December 16, 2020. https://doi.org/10.1101/2020.12.15.20248244
11. Riley S, Wang H, Eales O, Walters CE, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. REACT Round 8 Interim Report: SARS-CoV-2 Prevalence during the Initial Stages of the Third National Lockdown in England. MedRxiv January 22, 2021. https://doi.org/10.1101/2021.01.20.21250158
12. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, Fronterre C, Diggle PJ, Ashby D, CA Donnelly, Cooke G, Barclay W, Ward H, Taylor G, Darzi A, Elliott P. REACT Round 8 Final Report: High Average Prevalence with Regional Heterogeneity of Trends in SARS-CoV-2 infections in the Community England during January 2021. MedRxiv January 31, 2021.
https://doi.org/10.1101/2021.01.28.21250606
13. Riley S, Walters CE, Wang H, Eales O, Haw D, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi, Elliott P. REACT-1 round 9 interim report: Downward trend of SARS-CoV-2 in England in February 2021 but still at high prevalence. MedRxiv February 23, 2021. doi: https://doi.org/10.1101/2021.02.18.21251973
14. Riley S, Wang H, Eales O, Haw D, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi, Elliott P. REACT-1 round 9 final report: Continued but slowing decline of prevalence of Sars-Cov-2 during national lockdown in England in February 2021. MedrXiv March 6, 2021. https://doi.org/10.1101/2021.03.03.21252856
15. Riley S, Eales O, Haw D, Walters CE, Wang H, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi, Elliott P. REACT-1 round 10 report: Level prevalence of Sars-CoV-2 swab-positivity in England during third national lockdown in March 2021. MedRxiv April 15, 2021. https://doi.org/10.1101/2021.04.08.21255100
16. Elliott J, Whitaker M, Bodinier B, Riley S, Ward H, Cooke G, Darzi A, Chadeau-Hyam M, Elliott P. Symptom reporting in over 1 million people: community detection of COVID-19. MedRxiv Feb 12, 2021. https://www.medrxiv.org/content/10.1101/2021.02.10.21251480v1
17. Ward H, Cooke G, Whitaker M, Redd R, Eales O, Brown JC, Collet K, Cooper E, Daunt A, Jones K, Moshe M, Willicombe M, Day S, Atchison C, Darzi A, Donnelly CA, Riley S, Ashby D, Barclay WS, Elliott P. REACT-2 round 5: Increasing prevalence of Sars-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. Medrxiv March 1, 2021. doi: https://doi.org/10.1101/2021.02.26.21252512
18. Riley S, Haw D, Walters C, Wang H, Eales O, Ainslie K Atchison C, Fronterre C, Diggle P, Page A, Trotter A, Viet TL, Nabil-Fareed A, O'Grady J, The COVID-19 Genomics UK Consortium, Ashby D, Donnelly C, Cooke G, Barclay W, Ward H, Darzi A, Elliott P.REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown. MedRxiv May 17, 2021. doi: https://doi.org/10.1101/2021.05.13.21257144
19. Eales, O., Page, A. J., Tang, S., Walters, C., Wang, H., Haw, D., Trotter AJ, Viet TL, Foster-Nyarko E, Prosolek S, Atchison C, Ashby D, Cooke G, Barclay W, Donnelly C, O'Grady J, Volz E, The COVID-19 Genomics UK Consortium, Darzi A, Ward H, Elliott P, Riley, S. SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples. MedRxiv May 14, 2021. doi: https://doi.org/10.1101/2021.05.08.21256867
20. Davies B, Araghi M, Moshe M, Gao H, Bennet K, Jenkins J, Atchison C, Darzi A, Ashby D, Riley S, Barclay W, Elliott P, Ward H, Cooke G. Acceptability, usability and performance of laternal flow immunoassay tests for SARS-CoV-2 antibodies: REACT-2 study of self-testing in non-healthcare key workers. MedRxiv, June 27, 2021. doi: https://doi.org/10.1101/2021.06.21.21259254v2
21. Riley S, Wang H, Eales O, Haw D, Walters C, Ainslie K, Atchison C, Fronterre C, Diggle P, Page A, Prosolek S, Trotter AJ, Le Viet T, Alikhan N-F, The COVID-19 Genomics UK Consortium COG-UK, Ashby D, Donnelly C, Cooke G, Barclay W, Ward H, Darzi, Elliott P. REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant. MedRxiv June 21, 2021. doi: https://doi.org/10.1101/2021.06.17.21259103
22. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent symptoms following SARS-CoV02 infection in a random community sample of 508,707 people. https://doi.org/10.1101/2021.06.28.21259452 MedRxiv July 3, 2021.
23. Riley, S., Eales, O., Haw, D., Wang, H., Walters, C., Ainslie, K., Christina A, Fronterre C, Diggle P, Ashby D, Donnelly C, Barclay W, Cooke G, Ward H, Darzi A, Elliott, P. REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021. https://doi.org/10.1101/2021.07.08.21260185. MedRxiv July 8, 2021.
24. Cann, A., Clarke, C., Brown, J., Thomson, T., Prendecki, M., Moshe, M, Badhan A, Elliott P, Darzi A, Riley S, Ashby D, Willicombe M, Kelleher P, Randell P, Ward H, Barclay W, , Cooke, G. SARS-CoV-2 Antibody Lateral Flow Assay for antibody prevalence studies following vaccine roll out: a Diagnostic Accuracy Study. doi:10.1101/2021.07.14.21260488 MedRxiv July 16, 2021.
25. Ward, H., Whitaker, M., Tang, S., Atchison, C., Darzi, A., Donnelly, C., Diggle P, Ashby D, Riley S, Barclay W, Elliott P, Cooke, G. Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study. doi:10.1101/2021.07.14.21260497 MedRxiv July 18, 2021.
26. Ward, H., Atchison, C., Whitaker, M., Donnelly, C., Riley, S., Ashby, D., Darzi A, Barclay W, Cooke G, Elliott P, for the REACT study team. Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults. doi:10.1101/2021.07.21.21260926 MedRxiv July 22, 2021.
27. Eales O, Walters CE, Wang H, Haw D, Ainslie KEC, Atchison C, Page AJ, Prosolek SJ, Trotter AJ, Le Viet T, Alikhan N-F, Jackson LM, Ludden C, The COVID-19 Genomics UK (COG-UK) Consortium, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi A, Elliott P, Riley S. Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. MedRxiv Aug 13 2021.08.12.21261987; doi: https://doi.org/10.1101/2021.08.12.21261987
28. Elliott P, Haw D, Wang H, Eales O, Walters C, Ainslie K, Atchison C, Fronterre C, Diggle P, Page A, Trotter A, Prosolek S, COG-UK TCGUKC, Ashby D, Donnelly C, Barclay W, Cooke G, Ward H, Darzi A, Riley S. REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021.
doi: https://doi.org/10.1101/2021.09.02.21262979. MedRxiv Sept 10, 2021.
29. Chadeau-Hyam M, Wang H, Eales O, Haw D, Bodinier B, Whitaker M, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, Trotter AJ, The COVID-19 Genomics UK (COG0UK) Consortium, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Donnelly CA, Elliott P. REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England. doi: https://doi.org/10.1101/2021.10.14.21264965. MedRxiv Oct 22, 2021.
30. Chadeau-Hyam M, Eales O, Bodinier B, Wang H, Haw D, Whitaker M, Walters CE, Atchison C, Diggle PJ, Page AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Donnelly CA, Elliott P. REACT-1 round 15 interim report: High and rising prevalence of SARS-CoV-2 infection in England from end of September 2021 followed by a fall in late October 2021. doi: https://doi.org/10.1101/2021.11.03.21265877. MedRxiv Nov 3, 2021
31. Chadeau-Hyam, M., Eales, O., Bodinier, B., Wang, H., Haw, D., Whitaker, M. Walters C, Jonnerby J, Atchison C, Diggle P, Page A, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Donnelly C, Elliott, P. Spiral: REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection (imperial.ac.uk) Nov 18, 2021.
32. Elliott, P., Bodinier, B., Eales, O., Wang, H., Haw, D., Elliott, J., Whitaker M, Jonnerby J, Tang D, Walters C, Atchison C, Diggle P, Page A, Trotter A, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke G, Chadeau-Hyam M, Donnelly, C. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. MedRxiv, Dec 24, 2021. doi:10.1101/2021.12.22.21268252
33. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw D, Elliott J, Whitaker M, Walters C, Atchison C, Diggle P, Page A, Trotter A, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke G, Chadeau-Hyam M, Donnelly, C. Spiral: Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 (imperial.ac.uk) Jan 25, 2022.
34. Eales O, Ainslie KEC, Walters CE, Wang H, Atchison C, Ashby D, Donnelly CA, Cooke G, Barclay W, Ward H, Darzi A, Elliott P, Riley S. Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. MedRxiv 2022.02.04.22270426; doi: https://doi.org/10.1101/2022.02.04.22270426
35. Elliott P, Eales O, Bodinier B, Tang D, Wang H, Jonnerby J, Haw D, Elliott J, Whitaker M, Walters CE, Atchinson C, Diggle PJ, Page AJ, Trotter A, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke G, Chadeau-Hyam M, Donnelly CA. M./ Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022. MedRxiv 2022.02.03.22270365; doi: https://doi.org/10.1101/2022.02.03.22270365
36. Chadeau-Hyam M, Tang D, Eales O, Bodinier B, Wang H, Jonnerby J, Whitaker M, Elliott J, Haw
D, Walters CE, Atchison C, Diggle PJ, Page AJ, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Donnelly CA, Elliott P. The Omicron SARS-CoV-2 epidemic in England during February 2022. MedRxiv 2022.03.10.22272177; doi: https://doi.org/10.1101/2022.03.10.22272177. March 13, 2022.
37. Elliott, P., Eales, O., Steyn, N., Tang, D., Bodinier, B., Wang, H., Elliott J, Whitaker M, Atchison C, Diggle P, Trotter A, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke G, Donnelly C, Chadeau-Hyam, M. (2022). Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. https://www.imperial.ac.uk/SymplecticElements/repository.html?pub=1251291
38. Eales O, de Oliveira Martins L, Page AJ, Wang H, Bodinier B, Tang D, Haw D, Jonnerby J, Atchison C, Ashby D, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S, Elliott P, Donnelly CA, Chadeau-Hyam M. The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England. MedRxiv 2022.03.29.22273042; doi: https://doi.org/10.1101/2022.03.29.22273042
April 4, 2022.
39. Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, Donnelly CA, Chadeau-Hyam M, Elliott P. Variant-specific symptoms of COVID-19 among 1,542,510 people in England. MedRxiv 2022. 05.21.22275368; doi: https://doi.org/10.1101/2022.05.21.22275368 May 23, 2022.
40. Eales, O., Wang, H., Haw, D., Ainslie, K., Walters, C., Atchison, C., Cooke G, Barclay W, Ward H, Darzi A, Ashby D, Donnelly CA, Elliott P, Riley, S. (2022). Trends in SARS-CoV-2 infection prevalence during England’s roadmap out of lockdown, January to July 2021. MedRxiv doi: 10.1101/2022.06.02.22275900. June 2, 2022.
41. Atchison, C., Moshe, M., Brown, J., Whitaker, M., Wong, N., Bharath, A., McKendry RA, Darzi A, Ashby D, Donnelly CA, Riley S, Elliott P, Barclay WS, Cookee GS, Ward, H. (2022). Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay. MedRxiv. doi: 10.1101/2022.06.08.22276154. June 9, 2022.
Contact us
For survey queries only
Email admin@react.imperial.ac.uk
Please note that when support emails are answered, they will come from the email address support.react@cognitron.co.uk
Phone: 0207 365 8181
Support by phone and email will be available from 9am to 5pm, Monday to Friday
For general REACT enquiries
Email: react.study@imperial.ac.uk
Media
For media or communications enquiries only please contact: Jack Stewart